578 related articles for article (PubMed ID: 28825378)
1. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
2. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
Kosche C; Owen JL; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
[TBL] [Abstract][Full Text] [Related]
4. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune hypophysitis.
Ileana-Dumbrava E; Subbiah V
Lancet Oncol; 2018 Feb; 19(2):e123. PubMed ID: 29413466
[No Abstract] [Full Text] [Related]
9. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
10. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
12. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
Miller AH; Brock P; Jim Yeung SC
Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
[No Abstract] [Full Text] [Related]
13. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
14. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis.
Ohnuma T; Matsuzawa T; Kinoshita M; Sano S; Kawamura T; Shimada S; Inozume T
J Dermatol; 2017 Nov; 44(11):1325-1326. PubMed ID: 27864834
[No Abstract] [Full Text] [Related]
15. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
16. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
[TBL] [Abstract][Full Text] [Related]
17. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
18. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
19. [Endocrine side effects of checkpoint inhibitors].
Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA
Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042
[TBL] [Abstract][Full Text] [Related]
20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
